HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Related Keywords

San Antonio , Texas , United States , Saraa Hurvitz , Trastuzumab Emtansine , , Primary Analysis , Double Blind Phase , Previously Treated , Metastatic Breast , Partnership With , Antonio Breast Cancer Symposium , Breast Cancer , Her2 Metastatic Breast Cancer , Her2 Positive Metastatic Breast Cancer , Her2 Breast Cancer , Ther2 , Her2 Positive Breast Cancer , Her2climb 02 , Tucatinib , Sabcs , Clinical Implications ,